Researchers at Expansion Therapeutics are looking for adults with myotonic dystrophy type 1 (DM1) to participate in a phase 1 study. The goal of the study is to evaluate the safety of ERX-963. Researchers hope this therapy may improve symptoms of excessive daytime sleepiness and improve attention and memory. All participants will receive one dose . . .